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Sir,
We thank Dr Braillon for his interest in our recent systematic review
and meta-analysis, which examines published evidence of the relationship
between cancer survival outcome, vitamin D concentration and genetic
variation in vitamin D-related pathways. Braillon (2017) raises the issue
of the cut-offs in plasma 25-hydroxyvitamin D (25(OH)D3) concentra-
tion that we use as vitamin D ‘categories’. These are a consequence of the
conduct of original research included in our synthesis; unfortunately,
limitations of included studies are an inherent limitation of any
systematic review. One particular difficulty when synthesising evidence
from vitamin D studies arises from the inconsistent 25(OH)D cut-offs
used by researchers in creating statistically favourable conditions for their
respective study. Our work explicitly itemises the cut-offs used (Figure 2
in Vaughan-Shaw et al, 2017), in contrast to most previous reviews on
vitamin D that largely ignore the heterogeneity of category definitions.
This leads to between-study heterogeneity and makes the calculation of a
meaningful summary estimate challenging. It has been shown that the
benefit of vitamin D varies, and appears highest for the most deficient
(Talwar et al, 2007). Consequentially, heterogeneity affects the ability to
assess the true biological significance of vitamin D: different effect sizes
are often reported when comparing deficient (e.g., 10 nmol l 1) with
insufficient (e.g., 35 nmol l 1), vs comparing sufficient (e.g., 75 nmol l 1)
with super-sufficient (e.g., 100 nmol l 1). It is worth noting that a
significant association between 25(OH)D and cancer outcome was found
in our review, despite this cut-off heterogeneity.
Actually, one of the key messages of our paper was to highlight the
radically different vitamin D category definitions used in the extensive
discussion and supplementary materials. Our paper emphasises the need
to harmonise category definition in future studies. While using clinical
cut-offs of vitamin D deficiency/insufficiency (e.g., per Ross et al, 2011)
seems to be an obvious solution, two issues undermine this: first,
agreement on what these are has not been reached (and may indeed differ
for different outcomes), and second, due to large population differences
in 25(OH)D concentration the distribution of participants to any preset
categories may not be balanced, thereby negatively impacting on the
statistical power. Whether distributing subjects into defined 25(OH)D
categories is appropriate in any analysis is another issue. We found that
most studies (90%) used categories defined by intervals of plasma vitamin
D. However, we maintain that incorporating 25(OH)D level as a
continuous variable in any analysis is vastly preferable, because it can
account for non-linear vitamin D effects.
Dr Braillon further states that we did not adjust for main confounding
clinical variables. Indeed, some of the early studies included in our review
failed to adjust for some confounders. To mitigate against this, we used
the most fully adjusted estimates in the meta-analyses and systematically
assessed study quality – confounding factor assessment being one of our
quality criteria. Finally, we performed a stratified analysis based on
original study quality, thereby using all reasonable means to address this
issue in synthesis. Nonetheless, we agree that confounding remains an
issue for any observational study (or review), as many cancer risk factors
are also associated with vitamin D deficiency. In these circumstances,
demonstrated association with genetic factors involved in vitamin D
metabolism offers an important new perspective that supports a causal
link for vitamin D deficiency and cancer outcomes, in absence of RCTs.
This is why we conclude that our findings provide powerful background
rationale to instigate clinical trials to prospectively investigate the effect of
vitamin D on cancer outcomes.
Finally, in our view personalised medicine converges on the joint
consideration of phenotypic and genotypic data, since these are
biologically inseparable. Outcomes are affected by genotypes, phenotypes
and also by their complex interaction. In our review, we reported on the
impact of vitamin D phenotype (25(OH)D concentration) and vitamin
D-related genotype on cancer outcome. Previously, we reported an
interaction between genetic variation at the vitamin D receptor gene and
vitamin D levels which influenced colorectal cancer survival (Zgaga et al,
2014). Together, these support the premise that vitamin D supplementa-
tion trials should be stratified by genotype. Truly personalised medicine
will enable modification of the phenotype according to the genetic
predisposition, via more accurate subgroup classification.
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